<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055390</url>
  </required_header>
  <id_info>
    <org_study_id>158</org_study_id>
    <nct_id>NCT03055390</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women</brief_title>
  <official_title>Study the Effect of Intravenous Hyoscine Butylbromide Injection on the Duration and Progress of First Stage Labour in High Risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A case control trial Patients who meet the inclusion criteria were asked to participate in&#xD;
      the study and a written consent was obtained from each patient after explaining thoroughly&#xD;
      the nature and the scope of the study.&#xD;
&#xD;
      Patients were divided into three equal groups:&#xD;
&#xD;
      Group A: included 40 pregnant patients. They received two ml of normal saline intravenously&#xD;
      as a placebo.&#xD;
&#xD;
      Group B: included 40 pregnant patients. They received (20mg) hyoscine butylbromide (one ml&#xD;
      HBB+ one ml saline) intravenously.&#xD;
&#xD;
      Group C: included 40 pregnant patients .They received two ml (40 mg) hyoscine butylbromide&#xD;
      intravenously (HBB).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A case control trial Patients who meet the inclusion criteria were asked to participate in&#xD;
      the study and a written consent was obtained from each patient after explaining thoroughly&#xD;
      the nature and the scope of the study.&#xD;
&#xD;
      For each patient:&#xD;
&#xD;
        1. Complete history was taking to exclude allergy to hyoscine butylbromide, medical&#xD;
           disorders with pregnancy (preeclampsia, diabetes mellitus, heart disease â€¦etc.) and any&#xD;
           contraindication for vaginal delivery.&#xD;
&#xD;
        2. General examination of the patients including (pulse, blood pressure, temperature).&#xD;
&#xD;
        3. Obstetric Abdominal examination including fetal lie, fetal presentation, head station&#xD;
           and uterine contractions.&#xD;
&#xD;
        4. Vaginal examination including cervical dilatation, effacement and position, state of&#xD;
           fetal membranes, presenting part, position of fetal head and pelvic adequacy.&#xD;
&#xD;
        5. Obstetric ultrasound to detect fetal gestational age, fetal birth weight amount of&#xD;
           liquor, site of placental attachment and fetal heart rate.&#xD;
&#xD;
      Patients were divided into three equal groups:&#xD;
&#xD;
      Group A: included 40 pregnant patients. They received two ml of normal saline intravenously&#xD;
      as a placebo.&#xD;
&#xD;
      Group B: included 40 pregnant patients. They received (20mg) hyoscine butylbromide (one ml&#xD;
      HBB+ one ml saline) intravenously.&#xD;
&#xD;
      Group C: included 40 pregnant patients .They received two ml (40 mg) hyoscine butylbromide&#xD;
      intravenously (HBB).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of the first stage of labour</measure>
    <time_frame>24 hours</time_frame>
    <description>Duration of the first stage of labour</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vaginal Delivery</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They received two ml of normal saline intravenously as a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg hyoscine butylbromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg hyoscine butylbromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyoscine butylbromide</intervention_name>
    <description>Intravenous administration of hyoscine butylbromide during first stage of labor</description>
    <arm_group_label>20 mg hyoscine butylbromide</arm_group_label>
    <arm_group_label>40 mg hyoscine butylbromide</arm_group_label>
    <other_name>Dospa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2ml of saline intravenous</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 - 35 years old&#xD;
&#xD;
          2. Primigravdae or multigravida&#xD;
&#xD;
          3. Gestational age between completed 37- 41 weeks + 6 days.&#xD;
&#xD;
          4. Uncomplicated cephalic singleton pregnancy occipto-anterior position.&#xD;
&#xD;
          5. Established spontaneous active labour (defined as the presence of at least three&#xD;
             regular uterine contractions over 10 minutes with cervical dilatation three to four&#xD;
             centimeters) with cervical effacement not less than 50%.&#xD;
&#xD;
          6. Intact amniotic membranes.&#xD;
&#xD;
          7. High risk pregnancy (women with pregnancy induced hypertension- cardiac-Diabetes&#xD;
             Mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multigravidae.&#xD;
&#xD;
          2. Multiple fetus.&#xD;
&#xD;
          3. Malpresentation.&#xD;
&#xD;
          4. Patients with indications of elective caesarean section.&#xD;
&#xD;
          5. Medical conditions associated with pregnancy e.g. preeclampsia, diabetes mellitus.&#xD;
&#xD;
          6. Contraindications for hyoscine butylbromide which include known allergy to hyoscine or&#xD;
             other atropinics (e.g., atropine, scopolamine), myasthenia gravis, megacolon or&#xD;
             glaucoma.&#xD;
&#xD;
          7. Patients presented to causality with spontaneous rupture of membranes.&#xD;
&#xD;
          8. Spontaneous rupture of membranes during the active phase of first stage of labour.&#xD;
&#xD;
          9. Oxytocin induction or augmentation.&#xD;
&#xD;
         10. Patients who underwent epidural anesthesia or other types of analgesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Maged</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr Alainy medical school</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Maged</last_name>
    <phone>01005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Maged, MD</last_name>
      <phone>01005227404</phone>
      <email>prof.ahmedmaged@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed M Maged, MD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>hyoscine butylbromide</keyword>
  <keyword>progress of labor</keyword>
  <keyword>duration of labor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

